The contribution of fungi to the global economy

Niego, Allen Grace T.; Lambert, Christopher; Mortimer, Peter E.; Thongklang, Naritsada; Rapior, Sylvie; Grosse, Miriam; Schrey, Hedda; Charria-Girón, Esteban; Walker, Arttapon; Hyde, Kevin D.; Stadler, Marc

doi:10.1007/s13225-023-00520-9

Cited by 42 publications

(26 citation statements)

References 301 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[2] Even though most of the fungal natural product-derived drugs on the market were originally isolated from species of the Ascomycota, some of them were obtained from Basidiomycota. [3] For instance, the pleuromutilins are a family of sesquiterpenoid antibiotics produced by Clitopilus spp. (Agaricales, Basidiomycota) that are the most recent antibacterial drug class to make it to the market.…”

Section: Introductionmentioning

confidence: 99%

Depicting the Chemical Diversity of Bioactive Meroterpenoids Produced by the Largest Organism on Earth

Pfütze,

Charria‐Girón,

Schulzke

et al. 2024

Angew Chem Int Ed

Self Cite

View full text Add to dashboard Cite

In this investigation, we explored the diversity of melleolide‐type meroterpenoids produced by Armillaria ostoyae, one of the largest and oldest organisms on Earth, using extracts from liquid and solid fermentation media. The study unveiled three unprecedented dimeric bismelleolides (1‐3) and three novel fatty acid‐substituted congeners (4‐6), along with 11 new (7‐17) and 21 known (18‐38) derivatives. Structure elucidation was done by 1D‐ and 2D‐NMR spectroscopy, HRESI‐MS data, and ROESY spectral analysis for relative configurations. Absolute configurations were determined through crystal structures and ECD spectra comparison. A compound library of melleolide‐type meroterpenoids facilitated metabolomics‐wide associations, revealing production patterns under different culture conditions. The library enabled assessments of antimicrobial and cytotoxic activities, unveiling that the Δ2,4 double bond is not crucial for antifungal activity. Cytotoxicity was linked to the presence of an aldehyde at C‐1, but lost with a hydroxylation at C‐13. Chemoinformatic analyses demonstrated the intricate interplay of chemical modifications on biological properties. This study marks the first systematic exploration of Armillaria spp. meroterpenoid diversity via MS‐based untargeted metabolomics, offering insights into structure‐activity relationships through innovative chemoinformatics.

show abstract

Section: Introductionmentioning

confidence: 99%

Depicting the Chemical Diversity of Bioactive Meroterpenoids Produced by the Largest Organism on Earth

Pfütze,

Charria‐Girón,

Schulzke

et al. 2024

Angew Chem Int Ed

Self Cite

View full text Add to dashboard Cite

show abstract

“…Medicinal mushrooms are gaining increasing attention as emerging foods or functional supplements owing to their significant health benefits and diverse pharmacological activities, such as anticancer, antimicrobial, antioxidant, antidiabetic, and immunomodulatory effects. − In 2022, the global market size of medicinal mushrooms was nearly USD 10,000 million, and it is projected to further expand by USD 5939.97 million from 2022 to 2027 . Species commonly used in dietary supplements include Ganoderma lingzhi (Reishi), Grifola frondosa (maitake), Hericium erinaceus (lion’s mane), and Trametes versicolor (turkey tail) .…”

Section: Introductionmentioning

confidence: 99%

Discovery of New Antimicrobial Metabolites in the Coculture of Medicinal Mushrooms

Ji,

Tan,

Shang

et al. 2024

J. Agric. Food Chem.

View full text Add to dashboard Cite

Bioactivity screening revealed that the antifungal activities of EtOAc extracts from coculture broths of Trametes versicolor SY630 with either Vanderbylia robiniophila SY341 or Ganoderma gibbosum SY1001 were significantly improved compared to that of monocultures. Activity-guided isolation led to the discovery of five aromatic compounds (1−5) from the coculture broth of T. versicolor SY630 and V. robiniophila SY341 and two sphingolipids (6 and 7) from the coculture broth of T. versicolor SY630 and G. gibbosum SY1001. Tramevandins A−C (1−3) and 17-ene-1-deoxyPS ( 6) are new compounds, while 1-deoxyPS ( 7) is a new natural product. Notably, compound 2 represents a novel scaffold, wherein the highly modified p-terphenyl bears a benzyl substituent. The absolute configurations of those new compounds were elucidated by X-ray diffraction, ECD calculations, and analysis of physicochemical constants. Compounds 1, 2, and 5−7 exhibited different degrees of antimicrobial activity, and the antifungal activities of compounds 6 and 7 against Candida albicans and Cryptococcus neoformans are comparable to those of fluconazole, nystatin, and sphingosine, respectively. Transcriptome analysis, propidium iodide staining, ergosterol quantification, and feeding assays showed that the isolated sphingolipids can extensively downregulate the late biosynthetic pathway of ergosterol in C. albicans, representing a promising mechanism to combat antibiotic-resistant fungi.

show abstract

“…Fungi are eukaryotic organisms along with plants and animals with unique morphological, physiological, and nutritional traits ( Nagy et al, 2017 ), which contribute to their profound impact on human hosts ( Niego et al, 2023 ). In terms of human health, interest in fungi has grown exponentially in two opposite directions: first of all, the recognition of the major impact of fungal diseases that has prompted the World Health Organization to launch a list of priority fungal pathogens ( Table 1 and ( Rodrigues and Nosanchuk, 2023 )); as another consequence, the presence of commensal communities of fungi that colonize several sites of the human body ( Cui et al, 2013 ), with implications in human health and disease.…”

Section: Introductionmentioning

confidence: 99%

Harnessing inter-kingdom metabolic disparities at the human-fungal interface for novel therapeutic approaches

Costantini,

Pariano,

Puccetti

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Humans interact with a multitude of microorganisms in various ecological relationships, ranging from commensalism to pathogenicity. The same applies to fungi, long recognized for their pathogenic roles in infection–such as in invasive fungal diseases caused, among others, by Aspergillus fumigatus and Candida spp.–and, more recently, for their beneficial activities as an integral part of the microbiota. Indeed, alterations in the fungal component of the microbiota, or mycobiota, have been associated with inflammatory, infectious and metabolic diseases, and cancer. Whether acting as opportunistic pathogens or symbiotic commensals, fungi possess a complex enzymatic repertoire that intertwines with that of the host. In this metabolic cross-talk, fungal enzymes may be unique, thus providing novel metabolic opportunities to the host, or, conversely, produce toxic metabolites. Indeed, administration of fungal probiotics and fungi-derived products may be beneficial in inflammatory and infectious diseases, but fungi may also produce a plethora of toxic secondary metabolites, collectively known as mycotoxins. Fungal enzymes may also be homologues to human enzymes, but nevertheless embedded in fungal-specific metabolic networks, determined by all the interconnected enzymes and molecules, quantitatively and qualitatively specific to the network, such that the activity and metabolic effects of each enzyme remain unique to fungi. In this Opinion, we explore the concept that targeting this fungal metabolic unicity, either in opportunistic pathogens or commensals, may be exploited to develop novel therapeutic strategies. In doing so, we present our recent experience in different pathological settings that ultimately converge on relevant trans-kingdom metabolic differences.

show abstract

The contribution of fungi to the global economy

Cited by 42 publications

References 301 publications

Depicting the Chemical Diversity of Bioactive Meroterpenoids Produced by the Largest Organism on Earth

Depicting the Chemical Diversity of Bioactive Meroterpenoids Produced by the Largest Organism on Earth

Discovery of New Antimicrobial Metabolites in the Coculture of Medicinal Mushrooms

Harnessing inter-kingdom metabolic disparities at the human-fungal interface for novel therapeutic approaches

Contact Info

Product

Resources

About